UHNW AESTHETICS
01 / 10The Linda Evangelista Case
THE LINDA EVANGELISTA CASE
Read the context
Risk and decision points in a non-invasive treatment pathway
01 PUBLICLY REPORTED COURSE OF EVENTS
02 / 10A Timeline of Reported Consequences
01 PUBLICLY REPORTED COURSE OF EVENTSA Timeline of Reported ConsequencesMultiple treatments were followed by alleged physical, professional, social and psychological consequences.
02 MEDICAL AND TECHNICAL RISK FACTORS
03 / 10“Non-Invasive” Addresses Only One Dimension of Risk
02 MEDICAL AND TECHNICAL RISK FACTORS“Non-Invasive” Addresses Only One Dimension of RiskNo incision does not mean that indication, operator, device, repetition or follow-up are appropriate for the individual.
03 PHASE 1 | PROCEDURE-LEVEL BRIEFING
04 / 10Procedure-Specific Foundations Before Individual Review
03 PHASE 1 | PROCEDURE-LEVEL BRIEFINGProcedure-Specific Foundations Before Individual ReviewProfessor-led procedure knowledge structures any later, separately commissioned individual medical review.
04 PHASE 2 | SEPARATE PHYSICIAN ENGAGEMENT
05 / 10Individual Review in a Separate Physician-Patient Relationship
04 PHASE 2 | SEPARATE PHYSICIAN ENGAGEMENTIndividual Review in a Separate Physician-Patient RelationshipThe independently appointed physician acts under their own professional responsibility.
05 REVIEW POINTS IN THE CONTEXT OF THE CASE
06 / 10Every Subsequent Treatment Is a Separate Decision Point
05 REVIEW POINTS IN THE CONTEXT OF THE CASEEvery Subsequent Treatment Is a Separate Decision PointThe first treatment, every repeat application and the first unresolved finding require distinct review.
06 COUNTERFACTUAL ANALYSIS
07 / 10Potential Functions of Independent Oversight
06 COUNTERFACTUAL ANALYSISPotential Functions of Independent OversightThe framework identifies decision and escalation points without claiming that the actual outcome would have changed.
07 INDICATIVE ENGAGEMENT PARAMETERS
08 / 10How Complexity Changes the Engagement
07 INDICATIVE ENGAGEMENT PARAMETERSHow Complexity Changes the EngagementScope depends on procedures, disciplines, jurisdictions, review intervals, on-site availability and duration.
08 REVIEW FRAMEWORK AND SEPARATION OF ROLES
09 / 10Information and Individual Medicine Remain Separate
08 REVIEW FRAMEWORK AND SEPARATION OF ROLESInformation and Individual Medicine Remain SeparateProcedure-level information, medical responsibility and health-data processing sit within distinct engagements.
09 SOURCE BASIS AND LIMITS OF INFERENCE
10 / 10Public Sources and Methodological Constraints
09 SOURCE BASIS AND LIMITS OF INFERENCEPublic Sources and Methodological ConstraintsThe evidence defines established facts, open questions and the boundary of this hypothetical analysis.
VALIDATED ACCESSCOMPLETION
The next level begins with verified authority.
Further review materials are released following pre-validation, according to the indication and the authorised role.
Begin validationSwipe to continue
Chapter 1 / 10: The Linda Evangelista Case
UHNW AESTHETICS
01 / 10The Linda Evangelista Case
Risk and decision points in a non-invasive treatment pathway
Complete chapter record
UHNW AESTHETICS
THE LINDA EVANGELISTA CASE
Risk and Decision Points in a Non-Invasive Treatment Pathway
USD 50 million CLAIMED IN THE LITIGATION
No amount was awarded by a court; the settlement amount was not disclosed.1,11
According to her account, the consequences included physical, professional and social impact, with psychological distress continuing through 2025.1,8
KEY REVIEW POINTS
Independent medical and technical review
01 Before selecting the provider and device
02 Before each subsequent treatment
03 At the first unexplained finding
MEDICAL AND TECHNICAL REVIEW FRAMEWORK
M O N A C O